Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Esomeprazole/naproxen - Old API Wind-down/AstraZeneca

Drug Profile

Esomeprazole/naproxen - Old API Wind-down/AstraZeneca

Alternative Names: esomeprazole magnesium trihydrate/naproxen; Naproxen/esomeprazole; naproxen/esomeprazole magnesium trihydrate; PN-400; Vimovo

Latest Information Update: 16 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca; Cincinnati Children's Hospital Medical Center; POZEN
  • Developer AstraZeneca; Horizon Pharma; Old API Wind-down Ltd
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Anti-inflammatories; Antirheumatics; Naphthaleneacetic acids; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Prostaglandin synthase inhibitors; Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Ankylosing spondylitis; Osteoarthritis; Rheumatoid arthritis
  • Clinical Phase Unknown Juvenile rheumatoid arthritis

Most Recent Events

  • 15 May 2019 The United States Court of Appeals for the Federal Circuit reverses District Courts related to Vimovo patents
  • 06 Feb 2019 Aralez Pharmaceuticals is now called Old API Wind-down
  • 31 Dec 2018 Nuvo Pharmaceuticals in-licenses esomeprazole/naproxen from Horizon Pharma and Grunenthal
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top